Pharmaceuticals R&D is on the rail now… Hanmi, LG invest 20percents
Domestic pharmaceutical companies’ commitment to R&D is on the rail now.
According to the 2014 first half R&D status analysis by dailypharm, the companies put about 449.6 billion won which is 6.5 percent of its sales into R & D. It is 0.3% increase, in other words, 59.4 billion won increase. The...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
